Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience
Abstract Background Glioblastoma is usually diagnosed around the age of 60–70 years. Patients older than 65 years are frequently described as “elderly”. Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analyse...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-04-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13014-017-0809-9 |
| _version_ | 1817981082782400512 |
|---|---|
| author | Christoph Straube Hagen Scherb Jens Gempt Stefanie Bette Claus Zimmer Friederike Schmidt-Graf Jürgen Schlegel Bernhard Meyer Stephanie E. Combs |
| author_facet | Christoph Straube Hagen Scherb Jens Gempt Stefanie Bette Claus Zimmer Friederike Schmidt-Graf Jürgen Schlegel Bernhard Meyer Stephanie E. Combs |
| author_sort | Christoph Straube |
| collection | DOAJ |
| description | Abstract Background Glioblastoma is usually diagnosed around the age of 60–70 years. Patients older than 65 years are frequently described as “elderly”. Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analysed the outcome of elderly glioblastoma patients treated at our facility. Methods We performed a retrospective analysis of 62 consecutive patients older than 65 years treated for a primary glioblastoma at our facility from 2009 to 2015. Results Median age was 69.6 years (range 65.1–85.6 years); median OS of the entire cohort was 10.9 months. ECOG, MGMT and extent of resection but not age and the time from surgery to radiotherapy were associated with longer survival. Patients treated with adjuvant chemotherapy had a significantly longer survival (20.5 vs. 7.8 months). Furthermore, salvage therapies were associated with significant improved survival when compared to Best Supportive Care (22.3 vs. 8.8 months). Conclusion Also elderly patients are likely to benefit from an aggressive treatment after primary diagnosis of glioblastoma. |
| first_indexed | 2024-04-13T23:02:19Z |
| format | Article |
| id | doaj.art-e3a3f70e5eb64adc81fdd526bb8a4aa6 |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-04-13T23:02:19Z |
| publishDate | 2017-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-e3a3f70e5eb64adc81fdd526bb8a4aa62022-12-22T02:25:49ZengBMCRadiation Oncology1748-717X2017-04-011211910.1186/s13014-017-0809-9Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experienceChristoph Straube0Hagen Scherb1Jens Gempt2Stefanie Bette3Claus Zimmer4Friederike Schmidt-Graf5Jürgen Schlegel6Bernhard Meyer7Stephanie E. Combs8Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM)Institute of Computational Biology, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München (TUM)Department Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München (TUM)Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site MunichDepartment of Neurology, Klinikum rechts der Isar, Technische Universität München (TUM)Department of Neuropathology, Klinikum rechts der Isar, Technische Universität München (TUM)Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München (TUM)Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM)Abstract Background Glioblastoma is usually diagnosed around the age of 60–70 years. Patients older than 65 years are frequently described as “elderly”. Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analysed the outcome of elderly glioblastoma patients treated at our facility. Methods We performed a retrospective analysis of 62 consecutive patients older than 65 years treated for a primary glioblastoma at our facility from 2009 to 2015. Results Median age was 69.6 years (range 65.1–85.6 years); median OS of the entire cohort was 10.9 months. ECOG, MGMT and extent of resection but not age and the time from surgery to radiotherapy were associated with longer survival. Patients treated with adjuvant chemotherapy had a significantly longer survival (20.5 vs. 7.8 months). Furthermore, salvage therapies were associated with significant improved survival when compared to Best Supportive Care (22.3 vs. 8.8 months). Conclusion Also elderly patients are likely to benefit from an aggressive treatment after primary diagnosis of glioblastoma.http://link.springer.com/article/10.1186/s13014-017-0809-9Best Supportive CareGross Total ResectionMGMT Promotor MethylationKarnofsky Performance ScoreMGMT Methylation |
| spellingShingle | Christoph Straube Hagen Scherb Jens Gempt Stefanie Bette Claus Zimmer Friederike Schmidt-Graf Jürgen Schlegel Bernhard Meyer Stephanie E. Combs Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience Radiation Oncology Best Supportive Care Gross Total Resection MGMT Promotor Methylation Karnofsky Performance Score MGMT Methylation |
| title | Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience |
| title_full | Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience |
| title_fullStr | Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience |
| title_full_unstemmed | Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience |
| title_short | Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience |
| title_sort | does age really matter radiotherapy in elderly patients with glioblastoma the munich experience |
| topic | Best Supportive Care Gross Total Resection MGMT Promotor Methylation Karnofsky Performance Score MGMT Methylation |
| url | http://link.springer.com/article/10.1186/s13014-017-0809-9 |
| work_keys_str_mv | AT christophstraube doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT hagenscherb doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT jensgempt doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT stefaniebette doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT clauszimmer doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT friederikeschmidtgraf doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT jurgenschlegel doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT bernhardmeyer doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience AT stephanieecombs doesagereallymatterradiotherapyinelderlypatientswithglioblastomathemunichexperience |